In a recent survey, 94% of large, self-insured employers ranked high-cost pharmacy claims as the top threat to employer-sponsored healthcare coverage.
Specialty medicines now account for 55% of net spending, up from 28% in 2011.

Industry Insights

Orchard sets out to sell world’s priciest gene therapy

The role of analytics in enhancing content management strategies.

Learn More
Learn how PayRx can help you address the challenge of high-cost advanced therapeutics 
Need more help?
Contact us

PayRx is the industry leader in delivering tailored, on-demand precision risk financing solutions and analytics for self-insured employers and health plans to enable greater patient access to high-cost advanced therapies. We leverage data science, purpose-built technology and financial engineering to manage the cost impact of advanced therapies in a unique way that is significantly more affordable, flexible, and provides greater benefits.

Question 1 etiam enim dignissim arcu elementum?

Iaculis id magna arcu nibh magna orci nibh. Lorem donec arcu imperdiet sodales ut non praesent tristique est. Nunc vulputate morbi elit convallis. Consectetur etiam enim dignissim arcu elementum. Arcu orci, malesuada proin ac. Ornare odio morbi laoreet.

Question 2 etiam enim elementum?

Mi at diam nunc lorem aliquam quam parturient. Pharetra quam phasellus lorem eget felis sed a, sem. Consectetur donec scelerisque augue ullamcorper enim maecenas. Nulla a in amet, tristique ullamcorper vel. Nullam id fames faucibus ut.

Question 3 etiam enim dignissim arcu?

Vel eget malesuada velit ante nibh mauris lorem diam ultrices. Sit feugiat eu, adipiscing bibendum malesuada. Suspendisse turpis commodo magna at. Vestibulum neque integer enim neque condimentum. Faucibus vel nibh condimentum nibh hac aliquam ac.

Question 4 arcu elementum?

Ut cursus in fermentum habitant. Tincidunt ipsum vitae hendrerit tincidunt et. Varius sed quis at nascetur pretium lectus. Arcu quisque egestas tincidunt elementum ultricies blandit. Condimentum mauris, duis in ut ac mattis.